PharmaBiome is a privately-held spin-off company of ETH Zurich and a pioneer in the production of live biotherapeutic products to address disturbances of the gut microbiome. It has developed the first-in-the-industry, patent-protected technology platform for the production of standardized microbiome-based products. Founded in Zurich in 2015, at the intersection of microbiology, biotechnology, and data science, PharmaBiome believes that the future of microbiome-based therapeutics lies in developing the biotechnology needed to produce a solution compatible with the safety, efficiency, and trial requirements of any human medicine. This holds the promise of becoming a first step into the creation of personalized treatments for patients with chronic inflammatory diseases, immune conditions, and special nutritional needs. PharmaBiome has invested years in developing a biology-based analysis tool that allows for the identification and selection of the metabolic functions needed to restore the gut microbiome to a balanced state. The resulting formulation compounds the over 500 different strains that every person hosts to a minimal consortium of bacteria representing a healthy microbiome. The co-culture of this bacterial mix transforms it into a live biotherapeutic product whose active principle is based on the composition, function, and interactions between the microorganisms. The flexibility and speed of this process are a unique advantage to bring to life effective treatment options. Over the years, it has been recognized with several start-up awards such as Venture Kick, the ETH Spark Award, and the BaseLaunch Accelerator.